Clarapath, Medical Robotics Company, Raises $ 32 Million in Additional Funding

0

100-Year-Old Missing Link Fence: Dramatically Improves Pathology Workflow with Smart Robotics and Uses Proprietary Inputs for Next-Generation Precision Medicine and Care Paradigms

ClarapathStar Section

The company’s first robotic instrument, called SectionStar ™, is a fully automated system that is revolutionizing the reliability and efficiency of the pathology laboratory.

The company’s first robotic instrument, called SectionStar ™, is a fully automated system that is revolutionizing the reliability and efficiency of the pathology laboratory.

ClarapathStar Section

The company's first robotic instrument, called SectionStar®, is a fully automated system that is revolutionizing the reliability and efficiency of the pathology lab.

The company’s first robotic instrument, called SectionStar ™, is a fully automated system that is revolutionizing the reliability and efficiency of the pathology laboratory.

The company’s first robotic instrument, called SectionStar ™, is a fully automated system that is revolutionizing the reliability and efficiency of the pathology laboratory.

HAWTHORNE, NY, November 18, 2021 (GLOBE NEWSWIRE) – Clarapath, a robotics company aimed at catalyzing change in the way pathology labs process human and animal tissue, today announced follow-up funding, extending its Series B round with additional funding of $ 16 million , after the previous close of $ 16 million in Series B financing. The round included The 4100 Group, East Post Road Ventures (investment arm of White Plains Hospital), Epiphron Capital, Northwell Ventures, P5 Health Ventures and the involvement of other strategic organizations. This brings the total raised by Clarapath to over $ 39 million. Clarapath automates the processes around how tissue is processed on glass slides via a “cut” or cross section of the tissue sample.

Laboratory delays fueled by COVID-19, labor shortages and archaic methods

The company’s first robotic instrument, called SectionStar ™, is a fully automated system that is revolutionizing the reliability and efficiency of the pathology laboratory. This standardization of the quality of tissue sections is fundamental for the molecular mapping of human diseases and in the development of new treatment pathways.

A long overdue change, the current process is entirely manual, non-scalable, and dependent on a shrinking workforce. The COVID-19 pandemic has exacerbated labor shortages, creating unacceptable delays in the delivery of timely biopsy results and increasing healthcare costs. “As a manual process, AI-based algorithms for interpreting human tissue – particularly cancer – when examined at the cellular level are vulnerable to the variability in the quality of these tissue cross sections. Clarapath’s SectionStar combines many manual cutting, quality control and decision-making steps into one piece of equipment, resulting in higher quality tissue cuts, faster processing efficiency and lower overall costs , while providing richer data sets on these tissue samples, ”said Eric Feinstein, CEO of Clarapath, who was recently named one of the 40 Rising Stars Under 40 by the Business Council of Westchester.

“This funding will help further develop SectionStar with the goal of entering the non-clinical market in the very near future and targeting the large clinical market as an ultimate goal. The current funding will help us continue to build our team, as well as support a strong sales and service effort for our customers, ”added Feinstein.

SectionStar addresses a critical unmet industry need to produce faster, more accurate diagnostics, beyond anything we can achieve using the current histology workflow. “This not only dramatically increases the capacity of our histology laboratories, but places histology in the realm of reproducibility and quality required for AI-based disease diagnosis and the development of clinical medicine therapies. precision based on molecular morphology, ”said James Crawford, MD, PhD, SVP and Chair of Pathology and Laboratory Medicine at Northwell Health.

Improving patient care – follow the lead of radiology 25 years ago

The pathology follows in the footsteps of previous industry changes, including the shift to virtual imaging and teleradiology. “As a practicing radiologist, I have witnessed the shift from analog to digital technology, and how it has improved my ability as a clinician to provide more accurate diagnoses. Additionally, operations have been streamlined as the quality of imaging data has become less variable. Clarapath is shifting the pathology paradigm in a similar direction; Not only is the workflow streamlined and sample variability reduced, it ultimately opens up whole new areas for improving patient care at lower cost, ”said Scott Lancaster, MD, MBA, The 4100 Group.

From laboratory benches to pharmacy shelves

Clarapath today works closely with research and clinical clients including Northwell Health and The Ellison Institute. In the non-clinical setting, SectionStar will support the research and development of pharmaceutical products. “Conventional tissue processing based on 2D sections lacks a 3D context. The undeformed consecutive sections cut by the robotic device allow the superimposition of molecular and genomic markers. These datasets combined with advanced computer analyzes can transform non-clinical research into the diagnosis and development of therapies for cancer and other difficult diseases, ”said Partha Mitra, PhD, founder of Clarapath.

From human clinical markets to preclinical veterinary medicine and companion animals, this opportunity to add artificial intelligence (AI) to manual pathology practices will have a significant impact on routine and complex cases, setting a new standard for quality of biopsies. For more information on Clarapath and SectionStar, the first fully automated all-in-one sectioning and tissue transfer system, visit https://www.clarapath.com/.

About Clarapath

Clarapath is a medical robotics company aimed at catalyzing change in the way pathology laboratories operate. Clarapath develops workflow tools and solutions to improve results and reduce costs in clinical and non-clinical pathology. With the increasing demand for sample examinations and the reliance on a shrinking labor pool, SectionStar from Clarapath provides an automated section for non-clinical and clinical pathology laboratories. SectionStar is the first fully automated all-in-one tissue sectioning and transfer system that will dramatically increase capacity, reliability and consistency while minimizing the need for highly skilled labor. Clarapath is headquartered and leads its medical device development in Hawthorne, NY. It also has a CLIA-certified Clinical Research Organization (CRO) that serves clinical and research organizations by processing tissue, performing whole slide imaging, and providing automated image processing based in New York, New York. York Genome Center. For more information visit https://www.clarapath.com/.

Media contact:
Heidi davidson
Galvanize worldwide for Clarapath
[email protected]
(914) 441-6862

The photos accompanying this announcement are available on:
https://www.globenewswire.com/NewsRoom/AttachmentNg/2213454e-1ef0-408b-a167-323f5e1c5153
https://www.globenewswire.com/NewsRoom/AttachmentNg/adac7e44-2a2e-4bb8-89b1-80fabd041701

Share.

About Author

Comments are closed.